Farestone
Farestone Brand names, Farestone Analogs
Farestone Brand Names Mixture
- No information avaliable
Farestone Chemical_Formula
C26H28ClNO
Farestone RX_link
http://www.rxlist.com/cgi/generic2/toremifene.htm
Farestone fda sheet
Farestone msds (material safety sheet)
Farestone Synthesis Reference
R. J. Toivola et al., Eur. pat. Appl. 95,875; U.S. pat. 4,696,949 (1983, 1087 both to Farmos)
Farestone Molecular Weight
405.959 g/mol
Farestone Melting Point
108-110 oC
Farestone H2O Solubility
No information avaliable
Farestone State
Solid
Farestone LogP
6.725
Farestone Dosage Forms
Tablet
Farestone Indication
For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors
Farestone Pharmacology
Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.
Farestone Absorption
Well absorbed
Farestone side effects and Toxicity
No information avaliable
Farestone Patient Information
Patient Information:
Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.
Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.
Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.
Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.
Farestone Organisms Affected
Humans and other mammals
